Location of Repository

The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter?

By Jonathan Krell, Adam E Frampton and Justin Stebbing

Abstract

Tumor infiltrating lymphocytes (TILs) are commonly detected in breast tumors but their bearing on disease outcome is uncertain. The importance of TILs appears to be subtype-specific and varies depending on the histologic characteristics of the tumor. As our understanding of tumorigenesis is increasing the relevance of immunobiology will become apparent

Topics: Commentary
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3342888
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2009). AH: The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast.
    2. (2011). AR: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.
    3. (2011). C: The Immune Response to Tumors as a Tool toward Immunotherapy. Clinical & developmental immunology
    4. (2006). Croce CM: MicroRNA signatures in human cancers. Nature reviews Cancer
    5. (2005). Deciphering protein molecular signatures in cancer tissues to aid in diagnosis, prognosis, and therapy. Cancer Res
    6. (2006). et al: Type, density, and location Krell et al.
    7. (1988). et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
    8. (2003). Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res
    9. (2009). Jr: Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer immunity: a journal of the Academy of Cancer Immunology
    10. (2007). Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer.
    11. (2004). Mysliwski A:
    12. (2009). Tagliabue E, Balsari A: FOXP3 expression and overall survival in breast cancer.
    13. (2009). The effects of trastuzumab on
    14. (2010). Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
    15. (2009). Zolnierek A, et al: The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer research

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.